

# Long-term follow-up on health-related quality of life in major depressive disorder: A 2-year European cohort study

Delphine Saragoussi, Michael Cronquist Christensen, Lene Hammer-Helmich, Benoît Rive, Maëlys Touya, Josep Maria Haro

## SUPPLEMENTARY DATA

### Appendix 1

**Patient characteristics included in univariate analyses at baseline:** country at baseline (France, Germany, Spain, Sweden, UK); age at baseline (18–34, 35–54, 55–65 years); sex at baseline (male/female); educational level at baseline (no degree or diploma/elementary school, high school, non-university degree, university degree); switch of antidepressant at baseline (yes/no); patients' first depressive episode (yes/no); time since beginning of this depressive episode (<1 week, 1–2 weeks, 2–4 weeks, 4–8 weeks, >8 weeks); at least one anxiety symptom/disorder at baseline (yes/no); at least one other concomitant mental disorder at baseline (yes/no); at least one other chronic medical condition at baseline (yes/no); chronic pain or fibromyalgia at baseline (yes/no); chronic fatigue at baseline (yes/no); sleep disorders at baseline (yes/no); suicide attempt before baseline (yes/no); hospitalization for depression over the past 12 weeks before baseline (yes/no); sick leave within the past 12 months before baseline (yes/no); CGI-S score at baseline (1–3, 4, 5–7); PHQ-9 total score at baseline (0–4, 5–9, 10–14, 15–19, 20–27); and PDQ-5 total score at baseline (0–1<sup>st</sup> quartile, 1<sup>st</sup> quartile–median, median–3<sup>rd</sup> quartile, 3<sup>rd</sup> quartile–20).

**Patient characteristics included in univariate analyses at Month 2, Month 6/Month 12, and Month 18/Month 24:** country at baseline (France, Germany, Spain, Sweden, UK); age at baseline (18–34, 35–54, 55–65 years); sex at baseline (male/female); educational level at baseline (no degree or diploma/elementary school, high school, non-university degree, university degree); at least one other concomitant mental disorder at baseline (yes/no); chronic pain or fibromyalgia at baseline (yes/no); suicide attempt before baseline or between

baseline and Month 2 (yes/no); hospitalization for depression between baseline and Month 2 (yes/no); sick leave within the past 12 months before baseline, at baseline, or between baseline and Month 2 (yes/no); treatment line at Month 2 (1, 2,  $\geq 3$ ); antidepressant treatment stopped between baseline and Month 2 (yes/no); CGI-S score at Month 2 (1–3, 4, 5–7); PHQ-9 total score at Month 2 (0–4, 5–9, 10–14, 15–19, 20–27); and PDQ-5 total score at Month 2 (0–1<sup>st</sup> quartile, 1<sup>st</sup> quartile–median, median–3<sup>rd</sup> quartile, 3<sup>rd</sup> quartile–20).

**Table S1.** Summary of patient characteristics at baseline

<b>Patient characteristic</b>	<b>Analyzable population (N=1159)</b>
<b><i>Sociodemographics</i></b>	
Country (n)	
France	339
Spain	270
UK	341
Sweden	45
Germany	164
Age, mean $\pm$ SD (years)	44.3 $\pm$ 12.0
Female (%)	73.2
Marital status (%)	
Single	21.6
Married/couple	58.5
Divorced/separated	16.7
Widowed	3.2
Education (%)	
No degree or diploma	4.5
Elementary school	24.4
High school	36.9
Non-university degree	14.0
University degree	20.2
Work status (%)	
Paid employment or self-employed	66.8
Unemployed	17.8
<b><i>Characteristics of current depressive episode</i></b>	
Treating physician (% of patient group)	
General practitioner	83.6
Psychiatrist	16.4
Duration of episode (%) <sup>a</sup>	
<1 week	1.6
1–2 weeks	5.9
2–4 weeks	21.3
4–8 weeks	19.8
>8 weeks	51.4
Treatment <sup>b</sup>	
Initiating antidepressant therapy (%)	78.7
Switching antidepressant therapy (%)	21.3
Significant symptoms of anxiety (%) <sup>c</sup>	62.6
Anxiety disorders (%) <sup>d</sup>	45.5

Patient characteristic	Analyzable population (N=1159)
Questionnaire scores, mean ± SD	
SF-12 <sup>e</sup>	
PCS	45.2±12.1
MCS	26.5±9.2
EQ-5D utility score <sup>f</sup>	0.5±0.3
PHQ-9 <sup>g</sup>	17.6±5.3
CGI-S <sup>h</sup>	4.2±1.0
PDQ-5 <sup>i</sup>	11.4±4.6
<b>Other current illnesses</b>	
Mental-health disorders other than depression (%)	
Alcohol abuse or dependence	2.7
Other abuse disorders	1.3
Somatoform disorders	7.9
Eating disorders (anorexia, bulimia)	8.1
Other	0.6
Functional syndromes (%)	
Chronic pain	16.7
Chronic fatigue	16.1
Fibromyalgia	6.8
Premenstrual syndrome	3.5
Sleep disorders	28.2
Other	2.8
<b>Previous depressive episodes</b>	
History of depression (%)	
Previous episode <sup>j</sup>	56.6
Episode within previous 12 months if previous episode <sup>k</sup>	25.5
Antidepressant treatment if previous episode <sup>l</sup>	80.9
Previous hospitalization for depression <sup>k</sup>	8.9
Remission of previous episode <sup>k</sup>	83.2
Previous suicide attempt <sup>k</sup>	13.1

<sup>a</sup>Physicians' response. <sup>b</sup>N=1157; switching/initiating status unknown for two patients. <sup>c</sup>The percentage refers to patients "probably" or "definitely" presenting clinically significant symptoms of anxiety according to physician; total N=1158. <sup>d</sup>The percentage refers to patients "probably" or "definitely" meeting DSM-IV criteria for one or more of the anxiety disorders according to physician; N=1120. <sup>e</sup>N=912. <sup>f</sup>UK study population only; N=276. <sup>g</sup>N=940. <sup>h</sup>N=1155. <sup>i</sup>N=770. <sup>j</sup>N=1157. <sup>k</sup>N=655. <sup>l</sup>N=654.

**Abbreviations:** CGI-S, Clinical Global Impression–Severity of illness scale; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders (4th Edition); EQ-5D, EuroQol Five Dimensions questionnaire; MCS, mental component summary; PCS, physical component summary; PDQ-5, 5-item Perceived Deficit Questionnaire; PHQ-9, 9-item Patient Health Questionnaire; SD, standard deviation; SF-12, 12-item Short-Form Health Survey.

**Table S2.** Results of the univariate analyses of patient characteristics associated with SF-12 MCS and PCS scores at baseline, Month 2, and Month 6/Month 12. Data shown are coefficients ( $\pm$  standard error). Coefficients show the change in the respective score between the specified levels for each characteristic. Factors with  $P < 0.2$  in the univariate ANOVA were retained in the multivariate ANCOVA (shown in Table 1). A long dash indicates that an association with the characteristic listed was not assessed for this time point; a short dash (-) indicates the reference category.

Patient characteristic	Baseline <sup>a</sup>		Month 2 <sup>a</sup>		Month 6/Month 12 <sup>a</sup>	
	SF-12 MCS score	SF-12 PCS score	SF-12 MCS score	SF-12 PCS score	SF-12 MCS score	SF-12 PCS score
<b>Baseline sociodemographics</b>						
Country	$P < 0.001$	$P < 0.001$	$P < 0.001$	$P < 0.001$	$P = 0.030$	$P < 0.001$
France	$-2.76 \pm 0.95$	$1.13 \pm 1.25$	$0.44 \pm 1.13$	$2.11 \pm 1.23$	$1.35 \pm 1.11$	$3.32 \pm 1.09$
Spain	$0.87 \pm 0.99$	$-1.67 \pm 1.30$	$2.72 \pm 1.21$	$-0.82 \pm 1.32$	$1.64 \pm 1.17$	$-0.47 \pm 1.15$
UK	$-6.10 \pm 0.96$	$7.85 \pm 1.25$	$-2.54 \pm 1.12$	$6.84 \pm 1.21$	$-0.57 \pm 1.13$	$6.66 \pm 1.11$
Sweden	$-2.48 \pm 1.62$	$3.99 \pm 2.11$	$-3.02 \pm 1.97$	$3.71 \pm 2.14$	$-3.19 \pm 2.06$	$2.95 \pm 2.02$
Germany	-	-	-	-	-	-
Age (years)	$P < 0.001$	$P < 0.001$	$P < 0.001$	$P < 0.001$	$P = 0.016$	$P < 0.001$
18–34	$-5.11 \pm 0.87$	$7.36 \pm 1.14$	$-3.57 \pm 1.04$	$6.70 \pm 1.13$	$-2.94 \pm 1.06$	$7.07 \pm 1.04$
35–54	$-1.50 \pm 0.73$	$4.77 \pm 0.96$	$-0.78 \pm 0.86$	$3.83 \pm 0.94$	$-0.71 \pm 0.85$	$4.48 \pm 0.84$
55–65	-	-	-	-	-	-
Sex; male vs female	$P = 0.639$	$P = 0.002$	$P = 0.832$	$P = 0.336$	$P = 0.490$	$P = 0.298$
	$-0.32 \pm 0.69$	$2.72 \pm 0.90$	$-0.17 \pm 0.81$	$0.87 \pm 0.90$	$0.57 \pm 0.82$	$0.86 \pm 0.83$
Educational level	$P < 0.001$	$P < 0.001$	$P < 0.001$	$P < 0.001$	$P = 0.471$	$P < 0.001$
Elementary school	$3.43 \pm 0.86$	$-8.60 \pm 1.10$	$1.62 \pm 1.01$	$-8.27 \pm 1.08$	$0.44 \pm 1.01$	$-7.68 \pm 0.98$
High school	$0.34 \pm 0.82$	$-2.09 \pm 1.04$	$-1.41 \pm 0.96$	$-2.01 \pm 1.03$	$-0.57 \pm 0.97$	$-2.32 \pm 0.94$
Non-university degree	$1.49 \pm 1.05$	$-0.41 \pm 1.34$	$2.53 \pm 1.23$	$-0.82 \pm 1.32$	$1.07 \pm 1.23$	$-0.16 \pm 1.19$
University degree	-	-	-	-	-	-

Patient characteristic	Baseline <sup>a</sup>		Month 2 <sup>a</sup>		Month 6/Month 12 <sup>a</sup>	
	SF-12 MCS score	SF-12 PCS score	SF-12 MCS score	SF-12 PCS score	SF-12 MCS score	SF-12 PCS score
<b>Clinical characteristics</b>						
CGI-S score <sup>b</sup>	<i>P</i> <0.001	<i>P</i> <0.001	<i>P</i> <0.001	<i>P</i> <0.001	<i>P</i> <0.001	<i>P</i> <0.001
1–3	3.30±0.88	4.75±1.15	5.84±1.16	6.39±1.28	7.30±1.11	6.02±1.16
4	1.19±0.66	5.07±0.86	1.74±1.21	3.94±1.33	2.46±1.16	3.19±1.21
5–7	—	—	—	—	—	—
PHQ-9 score <sup>b</sup>	<i>P</i> <0.001	<i>P</i> <0.001	<i>P</i> <0.001	<i>P</i> <0.001	<i>P</i> <0.001	<i>P</i> <0.001
0–4	22.05±2.88	6.10±4.22	21.54±1.29	15.12±1.62	16.06±1.52	13.52±1.59
5–9	12.74±1.10	8.80±1.61	12.30±0.99	11.57±1.24	11.87±1.16	10.73±1.22
10–14	8.48±0.76	4.30±1.11	7.57±0.97	8.64±1.21	7.79±1.14	7.69±1.19
15–19	4.38±0.64	2.82±0.94	2.93±1.02	5.10±1.28	3.05±1.22	5.58±1.28
20–27	—	—	—	—	—	—
PDQ-5 score <sup>b</sup>	<i>P</i> <0.001	<i>P</i> <0.001	<i>P</i> <0.001	<i>P</i> <0.001	<i>P</i> <0.001	<i>P</i> <0.001
0–7	11.49±0.89	5.23±1.31	13.84±0.94	7.25±1.19	11.62±1.09	6.10±1.20
8–11	7.12±0.84	3.57±1.23	7.64±0.94	6.45±1.19	6.83±1.06	5.16±1.16
12–14	4.36±0.84	1.14±1.24	5.11±0.95	3.75±1.19	4.91±1.08	3.63±1.19
15–20	—	—	—	—	—	—
Patient's first depressive episode; yes vs no	<i>P</i> =0.990 −0.01±0.61	<i>P</i> =0.203 1.02±0.80	—	—	—	—
Time since the start of this depressive episode	<i>P</i> =0.073	<i>P</i> =0.075	—	—	—	—
<1 week	3.98±2.40	5.41±3.16				
1–2 weeks	2.37±1.29	−1.92±1.70				
2–4 weeks	1.61±0.79	1.18±1.03				
4–8 weeks	1.01±0.80	−1.34±1.06				
>8 weeks	—	—				
Suicide attempt <sup>c</sup> ; yes vs no	<i>P</i> =0.003 −3.60±1.22	<i>P</i> =0.045 −3.24±1.61	<i>P</i> =0.003 −4.05±1.35	<i>P</i> =0.291 −1.59±1.50	<i>P</i> <0.001 −5.38±1.32	<i>P</i> =0.062 −2.53±1.35
At least one anxiety symptom/disorder at baseline;	<i>P</i> =0.077 1.13±0.63	<i>P</i> <0.001 −3.73±0.83	—	—	—	—

Patient characteristic	Baseline <sup>a</sup>		Month 2 <sup>a</sup>		Month 6/Month 12 <sup>a</sup>	
	SF-12 MCS score	SF-12 PCS score	SF-12 MCS score	SF-12 PCS score	SF-12 MCS score	SF-12 PCS score
yes vs no						
At least one other concomitant mental disorder at baseline; yes vs no	<i>P</i> =0.051 1.64±0.84	<i>P</i> <0.001 -4.84±1.09	<i>P</i> =0.473 0.71±0.99	<i>P</i> <0.001 -3.73±1.09	<i>P</i> =0.139 -1.41±0.95	<i>P</i> <0.001 -3.63±0.96
At least one other chronic medical condition at baseline; yes vs no	<i>P</i> =0.118 1.08±0.69	<i>P</i> <0.001 -5.60±0.89	—	—	—	—
Chronic pain or fibromyalgia at baseline; yes vs no	<i>P</i> <0.001 4.32±0.75	<i>P</i> <0.001 -10.29±0.95	<i>P</i> =0.174 1.21±0.89	<i>P</i> <0.001 -9.11±0.93	<i>P</i> =0.030 -1.90±0.87	<i>P</i> <0.001 -9.05±0.83
Chronic fatigue at baseline; yes vs no	<i>P</i> =0.004 2.41±0.85	<i>P</i> <0.001 -5.46±1.10	—	—	—	—
Sleep disorders at baseline; yes vs no	<i>P</i> =0.672 0.29±0.68	<i>P</i> =0.004 -2.58±0.89	—	—	—	—
Hospitalization for depression <sup>d</sup> ; yes vs no	<i>P</i> =0.399 1.57±1.86	<i>P</i> =0.006 -6.74±2.44	<i>P</i> =0.480 -1.77±2.50	<i>P</i> =0.012 -6.84±2.73	<i>P</i> =0.558 -1.43±2.45	<i>P</i> =0.119 -3.92±2.51
Sick leave <sup>e</sup> ; yes vs no	<i>P</i> =0.267 -0.73±0.66	<i>P</i> =0.007 -2.34±0.86	<i>P</i> =0.010 -1.87±0.72	<i>P</i> =0.067 -1.47±0.80	<i>P</i> =0.301 -0.75±0.72	<i>P</i> =0.259 -0.83±0.73
<b>Treatment characteristics</b>						
Switch of antidepressant at baseline; yes vs no	<i>P</i> =0.598 0.39±0.75	<i>P</i> <0.001 -5.77±0.97	—	—	—	—
Treatment line at Month 2	—	—	<i>P</i> =0.002 0.82±1.76	<i>P</i> <0.001 6.16±1.93	<i>P</i> <0.001 3.92±1.63	<i>P</i> <0.001 6.17±1.65
1						
2			-2.14±1.86	1.57±2.03	-0.26±1.73	1.57±1.75
≥3			—	—	—	—
Antidepressant treatment stopped between baseline and Month 2; yes vs no	—	—	<i>P</i> =0.518 0.97±1.49	<i>P</i> =0.162 2.29±1.63	<i>P</i> =0.796 0.37±1.43	<i>P</i> =0.034 3.07±1.44

<sup>a</sup>Number of patients with an SF-12 assessment: Baseline, N=912; Month 2, N=807; Month 6, N=738; Month 12, N=702.

<sup>b</sup>Baseline CGI-S, PHQ-9 and PDQ-5 scores used in analysis of HRQoL outcomes at baseline; Month 2 CGI-S, PHQ-9 and PDQ-5 scores used in analysis of HRQoL outcomes at Month 2, Month 6/Month 12, and Month 18/ Month 24.

<sup>c</sup>Before baseline for HRQoL outcomes at baseline; before baseline or between baseline and Month 2 for HRQoL outcomes at Month 2, Month 6/ Month 12, and Month 18/ Month 24.

<sup>d</sup>Within 12 weeks before baseline for HRQoL outcomes at baseline; between baseline and Month 2 for HRQoL outcomes at Month 2, Month 6/ Month 12, and Month 18/ Month 24.

<sup>e</sup>Within 12 months before baseline for HRQoL outcomes at baseline; within 12 months before baseline or at baseline or between baseline and Month 2 for HRQoL outcomes at Month 2 and Month 6/Month 12.

**Abbreviations:** CGI-S, Clinical Global Impression–Severity of illness scale; HRQoL, health-related quality of life; MCS, mental component summary; PCS, physical component summary; PDQ-5, 5-item Perceived Deficit Questionnaire; PHQ-9, 9-item Patient Health Questionnaire; SF-12, 12-item Short-Form Health Survey

**Table S3.** Results of the univariate analyses of patient characteristics associated with EQ-5D utility index at baseline, Month 2, Month 6/Month 12, and Month 18/Month 24 (UK population only). Data shown are coefficients ( $\pm$  standard error). Coefficients show the change in the respective score between the specified levels for each characteristic. Factors with  $P < 0.2$  in the univariate ANOVA were retained in the multivariate ANCOVA (shown in Table 2). A long dash indicates that an association with the characteristic listed was not assessed for this time point; a short dash (-) indicates the reference category.

Patient characteristic	EQ-5D utility index <sup>a</sup>			
	Baseline	Month 2	Month 6/ Month 12	Month 18/ Month 24
<b>Baseline sociodemographics</b>				
Age (years)	$P=0.029$	$P=0.083$	$P=0.079$	$P=0.464$
18–34	0.05 $\pm$ 0.05	-0.07 $\pm$ 0.05	0.05 $\pm$ 0.05	0.05 $\pm$ 0.06
35–54	0.12 $\pm$ 0.05	0.02 $\pm$ 0.04	0.10 $\pm$ 0.05	0.06 $\pm$ 0.05
55–65	—	—	—	—
Sex; male vs female	$P=0.183$	$P=0.891$	$P=0.334$	$P=0.438$
	-0.05 $\pm$ 0.04	-0.00 $\pm$ 0.04	-0.04 $\pm$ 0.04	0.03 $\pm$ 0.04
Educational level	$P=0.376$	$P=0.499$	$P=0.027$	$P=0.005$
Elementary school	-0.01 $\pm$ 0.07	-0.10 $\pm$ 0.07	-0.17 $\pm$ 0.07	-0.26 $\pm$ 0.07
High school	0.01 $\pm$ 0.04	-0.04 $\pm$ 0.04	-0.08 $\pm$ 0.04	-0.11 $\pm$ 0.05
Non-university degree	0.00 $\pm$ 0.06	-0.02 $\pm$ 0.06	0.02 $\pm$ 0.06	-0.07 $\pm$ 0.07
University degree	—	—	—	—
<b>Clinical characteristics</b>				
CGI-S score <sup>b</sup>	$P < 0.001$	$P < 0.001$	$P = 0.003$	$P = 0.008$
1–3	0.03 $\pm$ 0.06	0.41 $\pm$ 0.09	0.24 $\pm$ 0.10	0.27 $\pm$ 0.10
4	0.02 $\pm$ 0.05	0.27 $\pm$ 0.09	0.14 $\pm$ 0.10	0.18 $\pm$ 0.10
5–7	—	—	—	—
PHQ-9 score <sup>b</sup>	$P < 0.001$	$P < 0.001$	$P < 0.001$	$P < 0.001$
0–4	NA	0.54 $\pm$ 0.06	0.45 $\pm$ 0.07	0.34 $\pm$ 0.08
5–9	0.32 $\pm$ 0.08	0.47 $\pm$ 0.04	0.39 $\pm$ 0.05	0.28 $\pm$ 0.06
10–14	0.22 $\pm$ 0.06	0.39 $\pm$ 0.04	0.34 $\pm$ 0.05	0.25 $\pm$ 0.06
15–19	0.16 $\pm$ 0.04	0.28 $\pm$ 0.04	0.22 $\pm$ 0.05	0.10 $\pm$ 0.06
20–27	—	—	—	—
PDQ-5 score <sup>b</sup>	$P < 0.001$	$P < 0.001$	$P < 0.001$	$P = 0.005$
0–7	0.29 $\pm$ 0.06	0.24 $\pm$ 0.05	0.17 $\pm$ 0.06	0.13 $\pm$ 0.06
8–11	0.21 $\pm$ 0.04	0.28 $\pm$ 0.04	0.20 $\pm$ 0.05	0.19 $\pm$ 0.05
12–14	0.21 $\pm$ 0.04	0.16 $\pm$ 0.04	0.12 $\pm$ 0.04	0.08 $\pm$ 0.05
15–20	—	—	—	—
Patient's first depressive episode; yes vs no	$P=0.470$	—	—	—
	0.03 $\pm$ 0.04			
Time since the start of this depressive episode	$P=0.505$	—	—	—
<1 week	0.20 $\pm$ 0.17			
1–2 weeks	-0.06 $\pm$ 0.08			

Patient characteristic	EQ-5D utility index <sup>a</sup>			
	Baseline	Month 2	Month 6/ Month 12	Month 18/ Month 24
2–4 weeks	0.02±0.06			
4–8 weeks	0.05±0.05			
>8 weeks	—			
Suicide attempt <sup>c</sup> ; yes vs no	<i>P</i> <0.001 −0.19±0.06	<i>P</i> =0.002 −0.17±0.05	<i>P</i> <0.001 −0.24±0.05	<i>P</i> <0.001 −0.21±0.06
At least one anxiety symptom/disorder at baseline; yes vs no	<i>P</i> <0.001 −0.12±0.03	—	—	—
At least one other concomitant mental disorder at baseline; yes vs no	<i>P</i> =0.087 −0.15±0.09	<i>P</i> =0.093 −0.13±0.08	<i>P</i> =0.905 −0.01±0.11	<i>P</i> =0.384 0.09±0.10
At least one other chronic medical condition at baseline; yes vs no	<i>P</i> =0.131 −0.07±0.04	—	—	—
Chronic pain or fibromyalgia at baseline; yes vs no	<i>P</i> =0.004 −0.17±0.06	<i>P</i> <0.001 −0.24±0.05	<i>P</i> <0.001 −0.20±0.05	<i>P</i> <0.001 −0.26±0.06
Chronic fatigue at baseline; yes vs no	<i>P</i> =0.465 −0.11±0.14	—	—	—
Sleep disorders at baseline; yes vs no	<i>P</i> =0.156 0.12±0.08	—	—	—
Hospitalization for depression <sup>d</sup> ; yes vs no	<i>P</i> =0.698 0.04±0.10	<i>P</i> =0.309 −0.20±0.19	<i>P</i> <0.001 −0.85±0.25	<i>P</i> <0.001 −0.85±0.25
Sick leave <sup>e</sup> ; yes vs no	<i>P</i> =0.014 −0.09±0.03	<i>P</i> =0.001 −0.11±0.03	<i>P</i> =0.059 −0.07±0.03	<i>P</i> =0.264 −0.04±0.04
<b>Treatment characteristics</b>				
Switch of antidepressant at baseline; yes vs no	<i>P</i> =0.044 −0.09±0.05	—	—	—
Treatment line at Month 2	—	<i>P</i> <0.001	<i>P</i> <0.001	<i>P</i> =0.003
1		0.16±0.09	−0.07±0.10	−0.01±0.11
2		−0.04±0.10	−0.24±0.10	−0.18±0.11
≥3		—	—	—
Antidepressant treatment stopped between baseline and Month 2; yes vs no	—	<i>P</i> =0.554 0.04±0.07	<i>P</i> =0.187 0.08±0.06	<i>P</i> =0.714 −0.03±0.07

<sup>a</sup>Number of patients with an EQ-5D assessment: Baseline, N=276; Month 2, N=261; Month 6, N=216; Month 12, N=196; Month 18, N=161; Month 24, N=160

<sup>b</sup>Baseline CGI-S, PHQ-9 and PDQ-5 scores used in analysis of HRQoL outcomes at baseline; Month 2 CGI-S, PHQ-9 and PDQ-5 scores used in analysis of HRQoL outcomes at Month 2, Month 6/ Month 12, and Month 18/ Month 24.

<sup>c</sup>Before baseline for HRQoL outcomes at baseline; before baseline or between baseline and Month 2 for HRQoL outcomes at Month 2, Month 6/Month 12, and Month 18/Month 24.

<sup>d</sup>Within 12 weeks before baseline for HRQoL outcomes at baseline; between baseline and Month 2 for HRQoL outcomes at Month 2, Month 6/ Month 12, and Month 18/ Month 24.

<sup>e</sup>Within 12 months before baseline for HRQoL outcomes at baseline; within 12 months before baseline or at baseline or between baseline and Month 2 for HRQoL outcomes at Month 2 and Month 6/Month 12.

**Abbreviations:** CGI-S, Clinical Global Impression–Severity of illness scale; EQ-5D, EuroQol Five Dimensions questionnaire; HRQoL, health-related quality of life; NA, not available; PDQ-5, 5-item Perceived Deficit Questionnaire; PHQ-9, 9-item Patient Health Questionnaire